Leigh MacMillan

May 8, 2023

Diabetes drugs associated with fewer adverse cardiac events in older veterans: study

Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.

By Leigh MacMillan
May 8, 2023

Improved imaging for kidney disease

Vanderbilt researchers identified optimal MRI parameters for estimating the severity of polycystic kidney disease, a common inherited disorder that can lead to end-stage renal failure.

By Leigh MacMillan
May 4, 2023

Tracking lung macrophages

A new technique will allow researchers to track subsets of immune cells that patrol and defend the lungs, to better understand the roles of these cells during lung inflammation, infection and injury.

By Leigh MacMillan
April 25, 2023

COVID alters respiratory microbiota

COVID-19 infection alters the microbes of the upper respiratory tract for at least several weeks, and such disturbances could impact disease severity and be targets for therapeutic interventions.

By Leigh MacMillan
April 24, 2023

Novel drugs have potential for treating tuberculosis

Drug-resistant tuberculosis is on the rise, and novel antibacterial drugs called SPTs have potential for treating the deadly lung infection.

By Leigh MacMillan
From left, Xiang Ye, PhD, Suba Rajendren, PhD, Antiana Richardson, and John Karijolich, PhD, are studying how the cancer-causing virus KSHV commandeers host gene expression and regulatory machinery.
April 20, 2023

Study details RNA editing in virus-infected cancer cells

Vanderbilt researchers detail the landscape of RNA editing — a form of RNA modification — in primary effusion lymphoma cells during Kaposi’s sarcoma-associated herpesvirus infection and identify an edited viral microRNA that is critical for infection.

By Leigh MacMillan